Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes

Giovanni Corrao; Antonella Zambon; Federica Nicotra; Carla Fornari; Carlo La Vecchia; Mario Mezzanzanica; Rossella E. Nappi; Luca Merlino; Giancarlo Cesana

doi:10.1016/j.maturitas.2007.03.001

Back

Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes

Article 2007 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2001

Oral Contraceptives, Hormone Replacement Therapy and Thrombosis

Frits R. Rosendaal, Frans M. Helmerhorst, Jan P. Vandenbroucke

Thrombosis and Haemostasis

Article2000

Continuation rates for oral contraceptives and hormone replacement therapy

Pier Giorgio Crosignani, Martin Birkhäuser, John A. Collins, Anna Glasier, U.‐F. Habenicht, Peter Kenemans, Carlo La Vecchia, Daniel R. Mishell, J. Court Stevenson, Basil C. Tarlatzis, D.T. Baird, E. Diczfalusy, Michele Meschìa, L. Puglisi, Sven O. Skouby

Article2002

[Adverse cardiovascular effects of postmenopausal hormone replacement therapy].

Saskia Middeldorp, H.R. Büller, Jan P. Vandenbroucke, FM Helmerhorst, Frits R. Rosendaal

PubMed

Article2004

Oral contraceptives, menopause hormone replacement therapy, and risk of stroke

Carlo La Vecchia

Article1996

Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer

Esteve Fernández, Carlo La Vecchia, Barbara D’Avanzo, Silvia Franceschi, Eva Negri, Fabio Parazzini